IGC Announces Issuance of Second Patent for the Treatment of Alzheimer's Using THC - IGC Pharma, INC.

Press

Releases

September 21, 2022

IGC Announces Issuance of Second Patent for the Treatment of Alzheimer’s Using THC

Related Posts

IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets

January 13, 2025

IGC Pharma Names IGC-AD1 Phase 2 Clinical Trial for Alzheimer’s Agitation “CALMA” and Expands Recruitment Strategy

January 8, 2025

IGC Pharma Expands Clinical Research for IGC-AD1, Addressing Cognitive Impairment and Underlying Pathology in Alzheimer’s

December 30, 2024

CEO Update

Recap of AAIC24 Conference Participation and Poster Presentations

August 28, 2024

Desk of CEO Marijuana Reclass

July 25, 2024